

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re Application of Dorothy French, et al. Serial No.: 10/516,868 Filed: December 3, 2004 For: COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR	Group Art Unit: 1632 Examiner: Not yet assigned Confirmation No: 1564 Customer No: 09157 CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. Date: <u>4-22-05</u> By: <u>Pam Golden</u> Pam Golden
--	---

REQUEST FOR A CORRECTED FILING RECEIPT

Mail Stop: Office of Initial Patent Examination
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

Sir:

Attached is a copy of the Official Filing Receipt received from the PTO in the above application for which issuance of a corrected filing receipt is respectfully requested. Please make the corrections as indicated on the attached copy and as follows:

Domestic Priority data as claimed by applicant:

**This application is a national stage filing of PCT/US03/17697 filed 06/04/03
 which claims benefit of U.S. Appln. No. 60/387,264 filed 06/07/02.**

Respectfully submitted,

GENENTECH, INC.

Date: 4/22/05

By: Cara Coburn
 Cara M. Coburn
 Reg. No. 46,631
 Telephone No. (650) 467-6222



1FW

Page 1 of 2

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY.DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/516,868	12/03/2004	1632	750	P1959R1	11	3	

09157
GENENTECH, INC.
1 DNA WAY
SOUTH SAN FRANCISCO, CA 94080

RECEIVED

MAR 29 2005

GENENTECH, INC.
LEGAL DEPT.

CONFIRMATION NO. 1564

FILING RECEIPT



OC000000015504474

Date Mailed: 03/22/2005

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Dorothy French, San Carlos, CA;
Avi J. Ashkenazi, San Mateo, CA;
Jean-Philippe F. Stephan, San Carlos, CA;
Luc Desnoyers, San Francisco, CA;

Power of Attorney: The patent practitioners associated with Customer Number 09157.

Domestic Priority data as claimed by applicant

This application is a 371 of PCT/US03/17697 06/04/2003
which claims benefit of U.S. Appln. No. 60/387,264, filed 06/07/02

Foreign Applications

Projected Publication Date: 06/30/2005

Non-Publication Request: No

Early Publication Request: No

Title

Compositions and methods for the diagnosis and treatment of tumor

Preliminary Class

435

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).